141 related articles for article (PubMed ID: 10946825)
1. Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain.
Pratelli A; Altamura M; Buonavoglia D; Pepe M; Tafaro A; Lembo A; Cirone F; Tempesta M; Jirillo E; Buonavoglia C
Immunopharmacol Immunotoxicol; 2000 Aug; 22(3):451-64. PubMed ID: 10946825
[TBL] [Abstract][Full Text] [Related]
2. Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose.
Buonavoglia C; Cavalli A; Tempesta M; Voight V; Buonavoglia D; Corrente M; Sagazio P
New Microbiol; 1995 Oct; 18(4):371-5. PubMed ID: 8590389
[TBL] [Abstract][Full Text] [Related]
3. Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection.
Larson LJ; Schultz RD
Am J Vet Res; 1997 Apr; 58(4):360-3. PubMed ID: 9099379
[TBL] [Abstract][Full Text] [Related]
4. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant?
Larson LJ; Schultz RD
Vet Ther; 2008; 9(2):94-101. PubMed ID: 18597247
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of two canine parvovirus vaccines for inducing seroconversion in Rottweiler and Doberman pinscher pups with various levels of maternally derived antibodies.
Coyne MJ
Vet Ther; 2000; 1(1):35-42. PubMed ID: 19757563
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c.
Wilson S; Illambas J; Siedek E; Stirling C; Thomas A; Plevová E; Sture G; Salt J
Vaccine; 2014 Sep; 32(42):5420-4. PubMed ID: 25148778
[TBL] [Abstract][Full Text] [Related]
7. Antibody levels and protection to canine parvovirus type 2.
Elia G; Cavalli A; Cirone F; Lorusso E; Camero M; Buonavoglia D; Tempesta M
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):320-2. PubMed ID: 16316392
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c.
Siedek EM; Schmidt H; Sture GH; Raue R
Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):58-64. PubMed ID: 21306055
[TBL] [Abstract][Full Text] [Related]
9. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
Gore TC; Lakshmanan N; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
Vet Ther; 2005; 6(1):5-14. PubMed ID: 15906266
[TBL] [Abstract][Full Text] [Related]
10. Immunization of pups with maternally derived antibodies to canine parvovirus (CPV) using a modified-live variant (CPV-2b).
Pratelli A; Cavalli A; Normanno G; De Palma MG; Pastorelli G; Martella V; Buonavoglia C
J Vet Med B Infect Dis Vet Public Health; 2000 May; 47(4):273-6. PubMed ID: 10861195
[TBL] [Abstract][Full Text] [Related]
11. Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine.
Larson LJ; Schultz RD
Vet Ther; 2007; 8(4):305-10. PubMed ID: 18183549
[TBL] [Abstract][Full Text] [Related]
12. Maternally-derived antibodies in pups and protection from canine parvovirus infection.
Decaro N; Campolo M; Desario C; Elia G; Martella V; Lorusso E; Buonavoglia C
Biologicals; 2005 Dec; 33(4):261-7. PubMed ID: 16168665
[TBL] [Abstract][Full Text] [Related]
13. Oral administration of modified live canine parvovirus type 2b induces systemic immune response.
Cavalli A; Desario C; Marinaro M; Losurdo M; Camero M; Decaro N; Catella C; Lanave G; Buonavoglia C
Vaccine; 2020 Jan; 38(2):115-118. PubMed ID: 31628031
[TBL] [Abstract][Full Text] [Related]
14. Intranasal vaccination of pups with maternally derived antibodies with a modified live canine parvovirus.
Buonavoglia C; Cavalli A; Gravino E; Voigt V; Buonavoglia D; de Caprariis D
Zentralbl Veterinarmed B; 1994 Mar; 41(1):3-8. PubMed ID: 7941844
[TBL] [Abstract][Full Text] [Related]
15. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus.
Spibey N; Greenwood NM; Sutton D; Chalmers WS; Tarpey I
Vet Microbiol; 2008 Apr; 128(1-2):48-55. PubMed ID: 18006253
[TBL] [Abstract][Full Text] [Related]
16. Three-year rabies duration of immunity in dogs following vaccination with a core combination vaccine against canine distemper virus, canine adenovirus type-1, canine parvovirus, and rabies virus.
Lakshmanan N; Gore TC; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
Vet Ther; 2006; 7(3):223-31. PubMed ID: 17039445
[TBL] [Abstract][Full Text] [Related]
17. Serologic response of pups to the low-passage, modified-live canine parvovirus-2 component in a combination vaccine.
O'Brien SE
J Am Vet Med Assoc; 1994 Apr; 204(8):1207-9. PubMed ID: 8014088
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the innate immune response in pups during canine parvovirus type 1 infection.
Decaro N; Altamura M; Pratelli A; Pepe M; Tinelli A; Casale D; Martella V; Tafaro A; Camero M; Elia G; Tempesta M; Jirillo E; Buonavoglia C
New Microbiol; 2002 Jul; 25(3):291-8. PubMed ID: 12173770
[TBL] [Abstract][Full Text] [Related]
19. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant properties of killed Propionibacterium avidum KP-40 in vaccination of dogs against canine parvovirosis.
Siwicki AK; Krzyzanowski J; Bartoszcze M; Mizak Z; Paluch S; Szmigielski S; Jeljaszewicz J; Pulverer G
Dtsch Tierarztl Wochenschr; 1998 May; 105(5):186-90. PubMed ID: 9646552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
